
    
      Each participant was treated until disease progression (DP), unacceptable toxicity, death,
      Investigator's decision or participant's refusal for further treatment (whichever come
      first). Participants were followed-up during treatment and for at least 30 days after its
      last study treatment (either Aflibercept or FOLFIRI) administration, up to a maximum of 6
      months.
    
  